FOI release

Treatment of haematological cancer

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2026/03106

Received 7 July 2026

Published 10 September 2026

Request

Q1. How many patients were treated with the following medicines in total regardless of diagnosis in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of monotherapy or combination Number patients treated

1.1 Glofitamab (Columvi) monotherapy
1.2 Glofitamab (Columvi) + Gemcitabine + Oxaliplatin (Glo + GEMOX)
1.3 Epcoritamab (Tepkinly)
1.4 Tafasitamab (Minjuvi)
1.5 Lenalidomide
1.6 Daratumumab (Darzalex)

2.1 Epcoritamab (Tepkinly) Monotherapy
2.2 Epcoritamab (Tepkinly) + Rituximab + Lenalidomide (E + R2)
2.3 Rituximab + Lenalidomide (R2)
2.4 Tafasitamab (Minjuvi) + Rituximab + Lenalidomide (Tafa + R2)

Q3. How many patients with a diagnosis of Multiple Myeloma were treated with the following medicines in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of medicine, combination or monotherapy Number patients treated

3.1 Daratumumab + Bortezomib + Thalidomide + Dexamethasone (DVTD)
3.2 Daratumumab + Lenalidomide + Dexamethasone (DRD)
3.3 Daratumumab + Bortezomib + Dexamethasone (DVD)
3.4 Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRD)
3.5 Daratumumab Monotherapy
3.6 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone (IVRD) 3.7 Isatuximab + Pomalidomide + Dexamethasone (IPD)
3.8 Isatuximab + Carfilzomib + Dexamethasone (IKD)
3.9 Belantamab mafodotin Monotherapy
3.10 Belantamab mafodotin + Bortezomib + Dexamethasone (BVD)
3.11 Belantamab mafodotin + Pomalidomide + Dexamethasone (BPD)
3.12 Lenalidomide + Dexamethasone (RD)
3.13 Lenalidomide Maintenance Monotherapy

Q4. How many patients with the following types of Myeloproliferative Disease were treated with the following medicines, in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of medicine All Types of Myeloproliferative Disease Myelofibrosis Polycythaemia Vera Essential Thrombocythaemia

4.1 Fedratinib (Inrebic)
4.2 Momelotinib (Omjjara)
4.3 Peginterferon Alfa-2a (Pegasys)
4.4 Ropeginterferon Alfa-2b (Besremi)
4.5 Ruxolitinib (Jakavi)

Response

Please could you answer the questions below in relation to the number of patients treated with these specific medicines from the 1st of April 2026 to the 30th of June 2026, or for the latest time-period you have data for. It would fantastic if you included data for all hospitals in your Trust.

For all questions, the latest data we have access to is from May 2026. I’ve therefore looked at a timeframe of 01/03/2026 – 31/05/2026.

Q1. How many patients were treated with the following medicines in total regardless of diagnosis in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available?
Name of monotherapy or combination Number patients treated
1.1 Glofitamab (Columvi) monotherapy <5 patients
1.2 Glofitamab (Columvi) + Gemcitabine + Oxaliplatin (Glo + GEMOX) <5 patients
1.3 Epcoritamab (Tepkinly) 8 patients
1.4 Tafasitamab (Minjuvi) 0 patients
1.5 Lenalidomide 181 patients
1.6 Daratumumab (Darzalex) 119 patients

Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.

Q2. How many patients with a diagnosis of Follicular Lymphoma were treated with the following medicines, in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available?
Name of monotherapy or combination Number patients treated
2.1 Epcoritamab (Tepkinly) Monotherapy <5 patients
2.2 Epcoritamab (Tepkinly) + Rituximab + Lenalidomide (E + R2) 0 patients
2.3 Rituximab + Lenalidomide (R2) 0 patients
2.4 Tafasitamab (Minjuvi) + Rituximab + Lenalidomide (Tafa + R2) 0 patients

Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.

Q3. How many patients with a diagnosis of Multiple Myeloma were treated with the following medicines in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available?
Name of medicine, combination or monotherapy Number patients treated
3.1 Daratumumab + Bortezomib + Thalidomide + Dexamethasone (DVTD) <5 patients
3.2 Daratumumab + Lenalidomide + Dexamethasone (DRD) 9 patients
3.3 Daratumumab + Bortezomib + Dexamethasone (DVD) 7 patients
3.4 Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRD) 0 patients
3.5 Daratumumab Monotherapy 106 patients
3.6 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone (IVRD) 9 patients
3.7 Isatuximab + Pomalidomide + Dexamethasone (IPD) <5 patients
3.8 Isatuximab + Carfilzomib + Dexamethasone (IKD) 0 patients
3.9 Belantamab mafodotin Monotherapy 15 patients
3.10 Belantamab mafodotin + Bortezomib + Dexamethasone (BVD) <5 patients
3.11 Belantamab mafodotin + Pomalidomide + Dexamethasone (BPD) <5 patients
3.12 Lenalidomide + Dexamethasone (RD) 28 patients
3.13 Lenalidomide Maintenance Monotherapy 169 patients

Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.

Q4. How many patients with the following types of Myeloproliferative Disease were treated with the following medicines, in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available?
Name of medicine All Types of Myeloproliferative Disease Myelofibrosis Polycythaemia Vera Essential Thrombocythaemia

Name of medicine	All Types	Myelofibrosis	Polycythaemia Vera	Essential Thrombocythaemia
4.1 Fedratinib (Inrebic) Myelofibrosis1	<5	<5	0	0
4.2 Momelotinib (Omjjara) 3	<5	<5	<5	<5
4.3 Peginterferon Alfa-2a (Pegasys) 1	<5	<5	0	0
4.4 Ropeginterferon Alfa-2b (Besremi)	0	0	0	0
4.5 Ruxolitinib (Jakavi) 10	26	10	13	<5

Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA.

Documents

There are no documents for this release.

This is Oxford University Hospitals NHS Foundation Trust's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.